These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37767538)

  • 1. Short-term safety of inactivated SARS-Cov-2 vaccines in Chinese patients with central nervous system inflammatory demyelinating diseases.
    Zhao D; Zhang W; Ma X; Zhao R; Yao L; Lu J; Yan X; Bai M; Zhang G; Li H; Guo J
    Vaccine X; 2023 Dec; 15():100388. PubMed ID: 37767538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
    Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H
    Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience.
    Monte G; Papetti L; Ferilli MAN; Ursitti F; Moavero R; Sforza G; Panella E; Tarantino S; Checchi MP; Vigevano F; Palma P; Valeriani M
    Front Immunol; 2023; 14():1106472. PubMed ID: 36761740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Research into Central Nervous System Inflammatory Demyelinating Diseases Related to COVID-19 Vaccines.
    Cheng MY; Ho HC; Hsu JL; Wang Y; Chen L; Lim SN; Liao MF; Ro LS
    Diseases; 2024 Mar; 12(3):. PubMed ID: 38534984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series.
    Ebrahimi N; Mazdak M; Shaygannejad V; Mirmosayyeb O
    Vaccine; 2023 Jan; 41(5):1003-1008. PubMed ID: 36635139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection.
    Stastna D; Menkyova I; Drahota J; Hrnciarova T; Kubala Havrdova E; Vachova M; Andelova M; Kleinova P; Kovarova I; Krasulova E; Preiningerova JL; Novakova I; Novotna K; Novotna M; Nytrova P; Pavlickova J; Srpova B; Storey K; Ticha V; Tyblova M; Uher T; Vodehnalova K; Horakova D
    Mult Scler Relat Disord; 2022 Sep; 65():104014. PubMed ID: 35803085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 and the risk of CNS demyelinating diseases: A systematic review.
    Lotan I; Nishiyama S; Manzano GS; Lydston M; Levy M
    Front Neurol; 2022; 13():970383. PubMed ID: 36203986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset of various CNS inflammatory demyelination diseases following COVID-19 vaccinations.
    Kim KH; Kim SH; Park NY; Hyun JW; Kim HJ
    Mult Scler Relat Disord; 2022 Dec; 68():104141. PubMed ID: 36037757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2-inactivated vaccine hesitancy and the safety in inflammatory bowel disease patients: a single-center study.
    Cao Y; Feng J; Duan S; Yang Y; Zhang Y
    Therap Adv Gastroenterol; 2022; 15():17562848221101722. PubMed ID: 35706827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated SARS-CoV-2 vaccine does not increase the risk of relapse in patients with clinically inactive adult-onset Still's disease.
    Hong X; Pan H; Su Y; Hu Q; Sun Y; Liu H; Cheng X; Ye J; Shi H; Meng J; Zhou Z; Jia J; Liu T; Wang M; Chen X; Ma Y; Tang Z; Wang F; Zhang H; You Y; Zhu D; Chen L; Yang C; Teng J; Chi H
    Rheumatology (Oxford); 2023 Jun; 62(6):2262-2266. PubMed ID: 36282541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on pathology of central nervous system inflammatory demyelinating diseases.
    Kalinowska-Łyszczarz A; Guo Y; Lucchinetti CF
    Neurol Neurochir Pol; 2022; 56(3):201-209. PubMed ID: 35758517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivated whole-virion SARS-CoV-2 vaccines and long-term clinical outcomes in patients with coronary atherosclerosis disease in China: a prospective cohort study.
    Xu H; Zheng J; Zhao X; Zhou Q; Fan B; Wu H; Zhang S; Ge J
    Cardiovasc Res; 2023 Jun; 119(6):1352-1360. PubMed ID: 36756815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of disease relapse, safety and tolerability of SARS-CoV-2 vaccination in patients with chronic inflammatory neuropathies.
    Doneddu PE; Briani C; Cocito D; Manganelli F; Fabrizi GM; Matà S; Mazzeo A; Fazio R; Benedetti L; Luigetti M; Inghilleri M; Ruiu E; Siciliano G; Cosentino G; Marfia GA; Carpo M; Filosto M; Antonini G; Notturno F; Sotgiu S; Cucurachi L; Dell'Aquila C; Bianchi E; Rosso T; Giordano A; Fernandes M; Campagnolo M; Peci E; Spina E; Tagliapietra M; Sperti M; Gentile L; Strano C; Germano F; Romozzi M; Moret F; Zarbo IR; Viola DV; Vegezzi E; Mataluni G; Cotti-Piccinelli S; Leonardi L; Carta A; Nobile-Orazio E;
    Eur J Neurol; 2023 Jul; 30(7):1907-1918. PubMed ID: 37000158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.
    Anamnart C; Tisavipat N; Owattanapanich W; Apiwattanakul M; Savangned P; Prayoonwiwat N; Siritho S; Rattanathamsakul N; Jitprapaikulsan J
    Mult Scler Relat Disord; 2022 Feb; 58():103414. PubMed ID: 35216789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination.
    Francis AG; Elhadd K; Camera V; Ferreira Dos Santos M; Rocchi C; Adib-Samii P; Athwal B; Attfield K; Barritt A; Craner M; Fisniku L; Iversen AKN; Leach O; Matthews L; Redmond I; O'Riordan J; Scalfari A; Tanasescu R; Wren D; Huda S; Leite MI; Fugger L; Palace J
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.
    Kim S; Seok HY
    Neurol Sci; 2023 Jun; 44(6):1841-1848. PubMed ID: 36781562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: a systematic review.
    Harel T; Gorman EF; Wallin MT
    Front Neurol; 2023; 14():1099758. PubMed ID: 37426444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.